Adventrx Granted Clearance in the UK for CoFactor Trial

Adventrx Pharmaceuticals has received clearance from the Medicines and Healthcare products Regulatory Agency to begin an international Phase IIb randomized controlled clinical trial using CoFactor with 5-fluorouracil (5-FU) in metastatic colorectal cancer in the UK.

The company expects to begin patient enrollment for this trial by the end of April 2005. The trial will be conducted at clinical sites in the European Union (EU) and countries outside of the EU following regulatory and ethics approval in each country.